Firmagon

(degarelix)

ApprovedSmall molecule

Degarelix is used to treat advanced prostate cancer by lowering testosterone levels in the body, which helps slow or stop cancer growth.[2] Firmagon is currently approved and in use across 17 indications[4].[1]

Firmagon is one of 431 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

110

Total Trials

Active Trials

430

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Prostate AdenocarcinomaApproved

Prostate NeoplasmActive, not recruiting

ToxicityActive, not recruiting

Prostate CarcinomaApproved

Benign Prostatic HyperplasiaActive, not recruiting

AdenocarcinomaApproved

Invasive Breast Ductal CarcinomaApproved

Metastatic Prostate CancerApproved

Breast CancerActive, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

Prostate AdenocarcinomaApproved

Approved

Prostate NeoplasmApproved

Active, not recruiting

ToxicityPhase 2

Active, not recruiting

Prostate CarcinomaApproved

Approved

Benign Prostatic HyperplasiaPhase 2

Active, not recruiting

AdenocarcinomaApproved

Approved

Invasive Breast Ductal CarcinomaApproved

Approved

Metastatic Prostate CancerApproved

Approved

Breast CancerPhase 2

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Firmagon

Ferring

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

DATROWAY

Daiichi Sankyo

Preclinical

4 7

Megace

Bristol-Myers Squibb

Preclinical

4 8

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 9

Lexiscan

Astellas

Preclinical

1 10

Adenocard

Astellas

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Prostate Cancer

NCT01990196

Q4 2026

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT05050084

Phase 2Active, not recruiting

Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849

Q1 2027

Phase 2Active, not recruiting

Prostate Cancer

NCT01786265

Q3 2027

Phase 2Recruiting

Prostate Cancer

NCT04734730

Clinical

Trials by Indication[1]

Prostate Cancer72 trials

The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer

Completed·LLund University·N/A·NCT04134130·33 enrolled

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Completed·UUniversity of Colorado, Denver·Phase 2·NCT02278185·19 enrolled

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Completed·UUniversity of Washington·Phase 2·NCT02849990·22 enrolled

Show 69 more trials

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05873192·30 enrolled

A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 2·NCT00116753·460 enrolled

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.

Completed· Ferring logo

Ferring··NCT02234089·461 enrolled

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Terminated· Ferring logo

Ferring·Phase 2·NCT00117312·37 enrolled

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Terminated· Ferring logo

Ferring·Phase 2·NCT00215657·131 enrolled

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

Completed· Astellas logo

Astellas·Phase 3·NCT01964170·234 enrolled

Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer

Active, not recruiting·TTurku University Hospital·Phase 1·NCT05917860·15 enrolled

A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT02526784·120 enrolled

An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer

Completed· Ferring logo

Ferring·Phase 2/3·NCT00215683·137 enrolled

A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer

Completed· Ferring logo

Ferring·Phase 4·NCT02726009·230 enrolled

A Long Term Safety Study of Degarelix in Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT00967018·77 enrolled

A Study of Degarelix in Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT00928434·409 enrolled

Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Terminated· Ferring logo

Ferring·Phase 3·NCT00831233·42 enrolled

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01751451·124 enrolled

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT03358563·30 enrolled

Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy

Completed·—·Phase 1·NCT02324998·20 enrolled

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04585932

Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists

Completed·RRabin Medical Center·Phase 4·NCT02475057·80 enrolled

Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT01542021·41 enrolled

Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT00801242·220 enrolled

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Unknown status·WWonju Severance Christian Hospital·Phase 4·NCT04248621·164 enrolled

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer

Not yet recruiting·UUniversity Health Network, Toronto·Phase 2·NCT04176081·208 enrolled

Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix

Completed· Ferring logo

Ferring··NCT03193645·150 enrolled

Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 2/3·NCT00268892·278 enrolled

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 1·NCT02468284·15 enrolled

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 2/3·NCT00117286·57 enrolled

A Degarelix Trial in Patients With Prostate Cancer

Terminated· Ferring logo

Ferring·Phase 3·NCT01242748·288 enrolled

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Completed· Ferring logo

Ferring·Phase 3·NCT01744366·285 enrolled

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer

Completed·—·Phase 1·NCT04301414·26 enrolled

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 2·NCT01491971·76 enrolled

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Recruiting·—·Phase 2·NCT04734730·70 enrolled

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Active, not recruiting·MMark Stein·Phase 2·NCT03951831·26 enrolled

Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT02799706·885 enrolled

Treatment of Prostate Cancer With Firmagon®

Completed·UUnited Clinic Management GmbH··NCT01710098·100 enrolled

The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer

Completed· Ferring logo

Ferring·Phase 2·NCT00819247·129 enrolled

Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

Completed·UUniversity of Washington·N/A·NCT01731912·16 enrolled

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02560051·19 enrolled

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01786265·310 enrolled

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Recruiting·MMayo Clinic·Phase 2·NCT06378866·532 enrolled

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

Withdrawn·—·Phase 2·NCT02159690

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT01990196·45 enrolled

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Completed· Ferring logo

Ferring·Phase 2·NCT00468286·133 enrolled

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Active, not recruiting·MMark Stein·Phase 1/2·NCT03689699·59 enrolled

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT04423211·804 enrolled

A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT06218667

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Active, not recruiting·PPraful Ravi, MB BCHir, MRCP·Phase 1·NCT05617885·9 enrolled

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Unknown status·BBritish Columbia Cancer Agency·Phase 2·NCT01630967·40 enrolled

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Not yet recruiting·BBaptist Health South Florida·Phase 2·NCT07455903·50 enrolled

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 2·NCT00738673·37 enrolled

Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients

Terminated· Ferring logo

Ferring·Phase 2·NCT00245466·88 enrolled

A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer

Terminated·OOttawa Hospital Research Institute·Phase 2·NCT01545882·5 enrolled

Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

Completed· Ferring logo

Ferring·Phase 2·NCT00818623·172 enrolled

Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer

Completed· Ferring logo

Ferring·Phase 2·NCT00819156·189 enrolled

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT00833248·246 enrolled

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT00295750·620 enrolled

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02494713·4 enrolled

A Trial of Degarelix in Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT00946920·859 enrolled

Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data

Completed·—··NCT04897958·14,417 enrolled

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07335796·30 enrolled

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 2·NCT00116779·127 enrolled

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT01220869·110 enrolled

Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

Completed· Ferring logo

Ferring··NCT02229253·112 enrolled

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01377389·30 enrolled

An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT02015871·206 enrolled

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Completed· Ferring logo

Ferring·Phase 3·NCT00884273·182 enrolled

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT03056638·56 enrolled

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Completed· Takeda logo

Takeda·Phase 2·NCT02135445·103 enrolled

Phase I/II Trial of Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Active, not recruiting·UUniversity of Wisconsin, Madison·Preclinical·NCT04989946·57 enrolled

PROfound Extension: Olaparib in mCRPC

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT04455750·387 enrolled

Metastatic Prostate Cancer6 trials

Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.

Completed·MMedical University of South Carolina·Phase 2·NCT03069937·52 enrolled

Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix

Unknown status·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 4·NCT03202381·35 enrolled

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT03678025·1,273 enrolled

Show 3 more trials

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Active, not recruiting·—·Phase 2·NCT03361735·25 enrolled

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed· Pfizer logo

Pfizer··NCT05701007·1,083 enrolled

Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·N/A·NCT02489357·12 enrolled

Prostate Adenocarcinoma4 trials

A Phase I/II Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer

Completed·SStanford University·Preclinical·NCT02346253·146 enrolled

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Active, not recruiting·NNRG Oncology·Phase 3·NCT05050084·2,050 enrolled

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Active, not recruiting·NNRG Oncology·Phase 3·NCT04513717·2,753 enrolled

Show 1 more trial

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Completed·NNRG Oncology·Preclinical·NCT03070886·612 enrolled

Prostatectomy3 trials

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01674270·35 enrolled

Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03080116·90 enrolled

Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy

Active, not recruiting·UUNICANCER·Phase 2·NCT01994239·120 enrolled

Benign Prostatic Hyperplasia2 trials

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

Completed· Ferring logo

Ferring·Phase 2·NCT00947882·404 enrolled

Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.

Completed· Ferring logo

Ferring·Phase 2·NCT00527488·52 enrolled

20 more indications

Neoadjuvant2 trials

TRial on the Endocrine Activity of Neoadjuvant Degarelix

Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT02005887·51 enrolled

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

Recruiting·—·Phase 1·NCT05839119·32 enrolled

Breast Cancer1 trial

Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT03947151·8 enrolled

MPA1 trial

Impact of Estradiol Addback

Completed·MMayo Clinic·Phase 1·NCT01862835·43 enrolled

Bladder Cancer1 trial

Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer

Unknown status·—··NCT04282876·60 enrolled

COVID-191 trial

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization

Completed·VVA Office of Research and Development·Phase 2·NCT04397718·96 enrolled

Obesity1 trial

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

Completed·UUniversity of Colorado, Denver·N/A·NCT02478775·99 enrolled

Ovarian Hyperstimulation1 trial

Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)

Completed·CCentre for Endocrinology and Reproductive Medicine, Italy·Phase 3·NCT01709942·80 enrolled

Cardiovascular Disease1 trial

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

Terminated· Ferring logo

Ferring·Phase 3·NCT02663908·545 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01746849·82 enrolled

AIN1 trial

Study to Find Maintenance Dose for Periodic Administration of ASP3550

Completed· Astellas logo

Astellas·Phase 2·NCT01261572·155 enrolled

Toxicity1 trial

Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

Completed·BBritish Columbia Cancer Agency·Phase 2·NCT01446991·50 enrolled

Tics1 trial

Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486

Completed· Ferring logo

Ferring·Phase 2·NCT00117949·82 enrolled

Ovarian Function1 trial

Cardiometabolic Consequences of the Loss of Ovarian Function

Recruiting·UUniversity of Colorado, Denver·Phase 4·NCT06264882·100 enrolled

Cardiovascular Events1 trial

Cardiovascular Events in GnRH Agonist vs. Antagonist

Unknown status·RRabin Medical Center·Phase 2·NCT04182594·80 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Firmagon® (Degarelix) for Injection

Completed· Ferring logo

Ferring··NCT02886598·368 enrolled

Endometriosis1 trial

Degarelix in the Treatment of Endometriosis Recurrence

Completed·CCentre for Endocrinology and Reproductive Medicine, Italy·Phase 3·NCT01712763·360 enrolled

IVF1 trial

Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix

Unknown status·AAssisting Nature·Phase 3·NCT03240159·120 enrolled

Acute Lymphoblastic Leukemia1 trial

Open-Label, Randomised Parallel-Group Study

Withdrawn· Ferring logo

Ferring·Phase 3·NCT00728533

Castration Sensitive Prostate Cancer1 trial

A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02020070·16 enrolled

Unspecified3 trials

ETHAN - ET for Male BC

Recruiting·JJose Pablo Leone·Phase 2·NCT05501704·60 enrolled

Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients

Completed· Ferring logo

Ferring·Phase 3·NCT01215513·127 enrolled

Firmagon (Degarelix) Intermittent Therapy

Terminated·CCanadian Urology Research Consortium·Phase 4·NCT01512472·144 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 24, 2008

FIRMAGON

NDA NDA022201

Sources

References

[1]
ClinicalTrials.gov — 110 trial records for degarelix. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Firmagon drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — degarelix compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for degarelix. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022201). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Firmagon. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Gonadotropin-Releasing Hormone Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Ferring

Patent Landscape[6]

Patent Cliff

Feb 10, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10973870Feb 10, 2029

10729739Feb 10, 2029

9579359Feb 10, 2029

12514898Feb 20, 2029

12533387Feb 20, 2029

4 more patents

11826397Apr 27, 2032

10695398Apr 27, 2032

11766468Apr 27, 2032

9415085Apr 27, 2032

Firmagon

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Prostate Cancer72 trials

Metastatic Prostate Cancer6 trials

Prostate Adenocarcinoma4 trials

Prostatectomy3 trials

Benign Prostatic Hyperplasia2 trials

Neoadjuvant2 trials

Breast Cancer1 trial

MPA1 trial

Bladder Cancer1 trial

COVID-191 trial

Obesity1 trial

Ovarian Hyperstimulation1 trial

Cardiovascular Disease1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

AIN1 trial

Toxicity1 trial

Tics1 trial

Ovarian Function1 trial

Cardiovascular Events1 trial

Safety and Efficacy1 trial

Endometriosis1 trial

IVF1 trial

Acute Lymphoblastic Leukemia1 trial

Castration Sensitive Prostate Cancer1 trial

Unspecified3 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News